Lyell Immunopharma (LYEL) Other Non Operating Income (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Other Non Operating Income data on file, last reported at $17.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 1267.48% year-over-year to $17.9 million; the trailing twelve-month figure through Mar 2026 stood at -$1.5 million (down 130.93% YoY), and the FY2025 full-year result was -$18.1 million, down 486.11% from the prior year.
• Other Non Operating Income climbed to $17.9 million in Q1 2026, from -$15.8 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $17.9 million in Q1 2026 to a low of -$15.8 million in Q4 2025.
• A 5-year average of $483352.9 and a median of $35000.0 in 2022 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income surged 6768.18% in 2022 and slumped 11200.0% in 2025, its largest moves.
• Tracing LYEL's Other Non Operating Income over 5 years: stood at $2.9 million in 2022, then slumped by 117.25% to -$506000.0 in 2023, then surged by 948.22% to $4.3 million in 2024, then sank by 467.08% to -$15.8 million in 2025, then soared by 213.7% to $17.9 million in 2026.
• Business Quant data shows LYEL's Other Non Operating Income at $17.9 million in Q1 2026, -$15.8 million in Q4 2025, and -$4.9 million in Q3 2025.